touchONCOLOGY were thrilled to speak to Editorial Board member Professor John Marshall (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022.
The phase III CheckMate 577 Study (NCT03044613): https://meetings.asco.org/abstracts-presentations/204867
KEYNOTE-062 (NCT02494583): https://meetings.asco.org/abstracts-presentations/204515
JCOG NExT study (UMIN000014795): https://meetings.asco.org/abstracts-presentations/204882
Questions:
- Could you give us a brief overview of neoantigen based therapies and their clinical development to date in upper gastrointestinal cancers? 00:16-02:41
- Which other recent advances in upper gastrointestinal cancers would you like to highlight? 02:47-3:57
Speaker Disclosure: John Marshall has no conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.
